Cabergoline
- PDF / 141,442 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 104 Downloads / 135 Views
1
S
Tricuspid regurgitation: case report A 62-year-old woman developed severe tricuspid regurgitation during treatment with low-dose cabergoline for acromegaly. The woman had previously undergone trans-sphenoidal surgery with partial resection of the tumour. She then received octreotide for control of the acromegaly. Subsequently she required treatment with cabergoline 0.5mg once daily [route not stated]. She was also receiving metformin, amlodipine and somatostatin. One year after starting cabergoline, she presented with a 2-month history of shortness of breath, ankle oedema and reduced functional capacity. An ECG showed left ventricular hypertrophy. The serum growth hormone level was 8.2 ng/mL. A 3/6 systolic murmur was noted on cardiac examination. Severe tricuspid regurgitation was observed on an echocardiogram. The tricuspid valve was thickened and retracted with restricted motion and the right heart chambers were enlarged with moderately impaired right ventricular systolic function. The woman received furosemide and her symptoms improved significantly. A referral was made to an endocrinologist for discontinuation of cabergoline. Author comment: "[T]here was a temporal association between the development of severe tricuspid regurgitation and the initiation of cabergoline treatment, as the patient’s tricuspid valve was reported to be normal on previous echocardiography." Izgi C, et al. Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly. Journal of Heart Valve Disease 19: 803049888 797-800, No. 6, Nov 2010 - Turkey
0114-9954/10/1340-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 26 Feb 2011 No. 1340
Data Loading...
